Allergy Therapeutics Plc and SWOT Analysis is a detailed company report covering company overview, history, SWOT, products, services, leadership team and strategy.

Report Name: Allergy Therapeutics Plc Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

Allergy Therapeutics Plc Report – Publisher: Research Cosmos

Price Scheme of the Report:

Single User License – USD 150

Team License – USD 175

Corporate License – USD 250

Allergy Therapeutics Plc – Business Description:

Allergy Therapeutics Plc  is a pharmaceutical company involved in manufacturing and marketing aluminium free allergy vaccines and diagnostics. The company has operations in the UK, Germany, Italy, Switzerland, Argentina, Austria, Spain, Portugal and the Netherlands. The company’s product of the includes vaccines such as Pollinex, Pollinex Quattro Grass, Pollinex Quattro Birch, Pollinex Quattro Ragweed, Pollinex Quattro Trees, Pollinex Quattro Grass & Birch, Pollinex Quattro Grass & Tree, Pollinex Quattro Grass &Mugwort, Acarovac MPL and Plus (house dust mite product), TyroMILBE, Venomil and TA Top; and oral vaccines such as Oralvac Grass, Oralvac Trees and Oralvac House Mite. In FY2017, the company’s Pollinex Quattro generated 45% of company’s total revenue followed by, Oralvac accounted 17%; Pollinex accounted 14%; third party products accounted 10%; TyroMILBE accounted 5%; Tyrosine S /TU accounted 4%; Venomil accounted 3%; AcarovacPlus accounted 2%; and Diagnostics accounted 1%. The company offers vaccines under the names Pollinex Quattro, Pollinex, TA Mix top and Venomil. Allergy Therapeutics offers vaccinations in various forms such as allergen-specific, named patient-specific and standard products in injectable and sublingual presentations. The company also offers Oralvac Compact Allergy Therapeutics also offers probiotic products that include Kallergen-Th, ATI Prob and Pollagen across Spain and Italyl. The products contain specific combinations of Lactobacilli and Bifidobacteria. The company also offers Acarovac Plus, a novel tyrosine-adsorbed, modified-allergen product developed for the treatment of perennial mite allergy. The company also offers licensed products that include DAP, a product used in the diagnosis of type one or immediate hypersensitivity to benzylpenicillin and related antibiotics (betalactams) by means of cutaneous tests (prick and intradermal). Allergy Therapeutics’ subsidiaries include the following: Allergy Therapeutics (Holdings) Ltd; Immunal Unipessoal, Lda.; Applied Molecular Development S.A.; Allergenome S.L.; Allergy Therapeutics Iberica S.L.; Bencard Allergie (Austria) GmbH and Bencard Allergy Therapeutics Unipessoal LDA. Geographically, the company classifies its segments into 10 regions, namely, Germany, Italy, Spain, Austria, the UK, the Netherlands, Switzerland, Czech Republic, Slovakia and other countries. In FY2017, Germany reported 59% of the company’s total revenue followed by Italy, 9%; Spain, 9%; Austria, 7%; the UK, 4%; the Netherlands, 4%; Switzerland, 3%; Czech Republic, 2%; Slovakia,2%; and other countries 1%.

Scope of the Report:

About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.

Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.

Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.

Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.

Key Questions Answered

What domain does Balfour Beatty plcoperate and what are key points about it?

What is the product/service portfolio of Atea ASA.?

How has Balfour Beatty plcperformed financially from 2013?

How does Balfour Beatty plcrank among its peers in terms of revenue and market share?

What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?

What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?

What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?

Reasons to buy

Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost

12 hour delivery time fulfilling your urgent requests as per your requirement

On-demand customization options that can completely cater to your needs by focusing the report on given specifics

For More Information, Get Sample of the report:Request Sample

Got Some Questions? Inquire Here:Inquire Before Buying

Get This Report:Purchase Now

For More Details, Contact Provider Directly:

Kevin Stewart
Sales Manager
Research Cosmos
+1 888 709 8757

Be the first to comment

Leave a Reply